In contrast, the high-risk group was enriched for CD66b+/MMP9+ (pro-tumor neutrophils), FAP+/collagen IV+ (extracellular-matrix-remodeling fibroblasts) and CD163+/MMP9+ (M2-like tumor-associated macrophages), reflecting distinct tumor microenvironments between the two groups. The gene discussed is MMP9; the disease is neoplasm.